Nasdaq
$6.84▲ 2.47%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $432.9MShares out 63.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 10.16Pre-market26.10.16 20:008-KKey event#●●●#●●●
REGENXBIO Inc.
Kenneth T. Mills will resign from the board of directors of REGENXBIO, effective October 21, 2026. Following his departure, George Migausky has been appointed as the new Chairman of the Board, while Daniel Tassé has stepped down as Lead Independent Director but remains a member of the board.…more
$6.84+2.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13Regular26.10.14 02:37SCHEDULE 13GOwnership
REGENXBIO Inc.
JPMorgan Chase & Co. has filed a Schedule 13G, reporting a beneficial ownership of more than 5% in REGENXBIO Inc. This filing formalizes the institution's stake in the company, which may influence future market sentiment regarding the stock.…more
$6.84+2.47%vs prev closeView filingShare - 9.23After-hours26.09.24 05:058-KKey event
REGENXBIO Inc.
REGENXBIO has entered into a settlement agreement with Sarepta Therapeutics and Catalent to resolve all ongoing patent infringement litigation. Under the terms, Sarepta will pay $39.0 million to REGENXBIO, and both parties have agreed to dismiss all pending litigation and established a covenant not to sue regarding the specified patents.…more
$6.84+2.47%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.25Overnight26.09.25 16:18#●●●#●●●#●●●
REGENXBIO Reports Positive 3-Year Data for Sura-Vec Gene Therapy
REGENXBIO's gene therapy candidate, sura-vec, demonstrated significant improvement in diabetic retinopathy patients over a three-year period without vision-threatening events. The company confirmed long-term safety and efficacy, though regulatory milestones remain ahead.…more
$6.84+2.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.23After-hours26.09.24 05:14
●●●●●●●● ●●●●● ●●●●●●
REGENXBIO has reached a settlement with Sarepta Therapeutics to resolve all patent litigation regarding Elevidys for $39 million. This agreement effectively removes legal uncertainty and provides the company with a cash infusion.…more
$6.84+2.47%vs prev closeShareBenzinga - 8.24Pre-market26.08.24 21:21
●●●●●●●● ●●●●● ●●●●●●
Regenxbio shares fell after the FDA placed a clinical hold on its gene therapy candidate RGX-121 due to asymptomatic spine MRI findings in trial participants. The company stated it does not expect to resubmit its BLA in the near term, signaling a delay in development.…more
$6.84+2.47%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report